^
    3d
    Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL (clinicaltrials.gov)
    P2, N=29, Recruiting, The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    Rituxan (rituximab) • Jaypirca (pirtobrutinib) • lisaftoclax (APG-2575)
    2ms
    APG2575AC101: Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML (clinicaltrials.gov)
    P1/2, N=458, Recruiting, Ascentage Pharma Group Inc. | N=284 --> 458 | Trial completion date: Aug 2026 --> Sep 2029 | Trial primary completion date: Aug 2025 --> Sep 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    azacitidine • Nailike (olverembatinib) • lisaftoclax (APG-2575) • Synribo (omacetaxine mepesuccinate)
    3ms
    Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=62, Not yet recruiting, First Affiliated Hospital of Zhejiang University
    New P1/2 trial • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • prednisone • lisaftoclax (APG-2575) • Synribo (omacetaxine mepesuccinate)
    4ms
    MAPLE-1: APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia (clinicaltrials.gov)
    P1, N=46, Completed, Ascentage Pharma Group Inc. | Trial completion date: Feb 2024 --> Aug 2025
    Trial completion date
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • lisaftoclax (APG-2575)
    8ms
    Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL (clinicaltrials.gov)
    P1, N=144, Recruiting, Ascentage Pharma Group Inc. | N=35 --> 144 | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Mar 2025 --> Oct 2025
    Enrollment change • Trial completion date • Trial primary completion date
    |
    lisaftoclax (APG-2575)
    9ms
    The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy. (PubMed, Signal Transduct Target Ther)
    The first BCL2-selective BH3-mimetic, venetoclax, showed remarkable efficacy with manageable toxicities and has transformed the treatment of several hematologic malignancies. Following its success, several chemically similar BCL2 inhibitors such as sonrotoclax and lisaftoclax are currently under clinical evaluation, alone and in combination...Tumor-specific BCL-XL or MCL1 inhibition may be achieved by novel targeting approaches using PROTACs or selective drug delivery strategies and would be transformational in many subtypes of malignancy. Taken together, we envision that the targeting of BCL2 proteins, while already a success story of translational research, may in the foreseeable future have broader clinical applicability and improve the treatment of multiple diseases.
    Review • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1)
    |
    Venclexta (venetoclax) • lisaftoclax (APG-2575) • sonrotoclax (BGB-11417)
    10ms
    Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4). (clinicaltrials.gov)
    P3, N=464, Recruiting, Ascentage Pharma Group Inc. | Not yet recruiting --> Recruiting | Initiation date: Oct 2024 --> Jan 2025
    Enrollment open • Trial initiation date
    |
    azacitidine • lisaftoclax (APG-2575)
    1year
    Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4). (clinicaltrials.gov)
    P3, N=464, Not yet recruiting, Ascentage Pharma Group Inc.
    New P3 trial • Combination therapy
    |
    azacitidine • lisaftoclax (APG-2575)
    1year
    APG2575AC101: Study of APG2575 Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML (clinicaltrials.gov)
    P1/2, N=284, Recruiting, Ascentage Pharma Group Inc. | Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Aug 2024 --> Aug 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    azacitidine • lisaftoclax (APG-2575) • Synribo (omacetaxine mepesuccinate)
    1year
    A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus. (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Ascentage Pharma Group Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lisaftoclax (APG-2575)
    over1year
    A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=30, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    decitabine • Nailike (olverembatinib) • lisaftoclax (APG-2575)
    over1year
    A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer (clinicaltrials.gov)
    P1/2, N=65, Suspended, Ascentage Pharma Group Inc. | Recruiting --> Suspended
    Trial suspension • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    Ibrance (palbociclib) • lisaftoclax (APG-2575)